J P Steinbach

Summary

Country: Germany

Publications

  1. ncbi request reprint CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity
    Joachim P Steinbach
    Department of Neurology, University of Tubingen, School of Medicine, Germany
    Brain Pathol 12:12-20. 2002
  2. ncbi request reprint Surviving glioblastoma for more than 5 years: the patient's perspective
    J P Steinbach
    Department of General Neurology, Hertie Institute for Clinical Brain Research, Tubingen, Germany
    Neurology 66:239-42. 2006
  3. ncbi request reprint Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death
    Joachim P Steinbach
    Laboratory of Molecular Neuro Oncology, Department of Neurology, University of Tubingen, Medical School, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    J Neurochem 92:1340-9. 2005
  4. ncbi request reprint Delayed resolution of white matter changes following therapy of B burgdorferi encephalitis
    Joachim P Steinbach
    Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, School of Medicine, Germany
    Neurology 64:758-9. 2005
  5. ncbi request reprint Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis
    Joachim P Steinbach
    Laboratory of Molecular Neuro Oncology, Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, School of Medicine, Hoppe Seylerstr 3, 72076 Tuebingen, Germany
    Biochem Biophys Res Commun 321:524-30. 2004
  6. ncbi request reprint Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death
    Joachim P Steinbach
    Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, School of Medicine, Tubingen, Germany
    Cancer Res 64:1575-8. 2004
  7. ncbi request reprint Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death
    J P Steinbach
    Laboratory of Molecular Neuro Oncology, Department of Neurology, University of Tubingen, School of Medicine, Tubingen, Germany
    Cell Death Differ 10:823-32. 2003
  8. ncbi request reprint Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
    Ulrich Herrlinger
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany
    J Clin Oncol 24:4412-7. 2006
  9. ncbi request reprint One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma
    W Wick
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen Medical School, Germany
    Neurology 62:2113-5. 2004
  10. ncbi request reprint Identification by suppression subtractive hybridization of p21 as a radio-inducible gene in human glioma cells
    A Rimner
    Department of Neurology, , School of Medicine, Germany
    Anticancer Res 21:3505-8. 2001

Detail Information

Publications25

  1. ncbi request reprint CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity
    Joachim P Steinbach
    Department of Neurology, University of Tubingen, School of Medicine, Germany
    Brain Pathol 12:12-20. 2002
    ....
  2. ncbi request reprint Surviving glioblastoma for more than 5 years: the patient's perspective
    J P Steinbach
    Department of General Neurology, Hertie Institute for Clinical Brain Research, Tubingen, Germany
    Neurology 66:239-42. 2006
    ..Depression and anxiety were common. Although most patients thought that their social functioning and work ability were impaired, little reduction in overall quality of life was perceived...
  3. ncbi request reprint Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death
    Joachim P Steinbach
    Laboratory of Molecular Neuro Oncology, Department of Neurology, University of Tubingen, Medical School, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    J Neurochem 92:1340-9. 2005
    ..These results suggest that death ligands may be useful to target hypoxic tumour cells resistant to conventional therapies or to complement strategies aiming at the induction of tumour hypoxia...
  4. ncbi request reprint Delayed resolution of white matter changes following therapy of B burgdorferi encephalitis
    Joachim P Steinbach
    Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, School of Medicine, Germany
    Neurology 64:758-9. 2005
  5. ncbi request reprint Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis
    Joachim P Steinbach
    Laboratory of Molecular Neuro Oncology, Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, School of Medicine, Hoppe Seylerstr 3, 72076 Tuebingen, Germany
    Biochem Biophys Res Commun 321:524-30. 2004
    ..These findings suggest that adding inhibitors of IGF-1R may be a strategy to overcome escape from the anti-apoptotic effects of EGFR inhibition in malignant gliomas...
  6. ncbi request reprint Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death
    Joachim P Steinbach
    Department of Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, School of Medicine, Tubingen, Germany
    Cancer Res 64:1575-8. 2004
    ..These results caution that therapies targeting EGFR signaling pathways can protect tumor cells from acute hypoxia...
  7. ncbi request reprint Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death
    J P Steinbach
    Laboratory of Molecular Neuro Oncology, Department of Neurology, University of Tubingen, School of Medicine, Tubingen, Germany
    Cell Death Differ 10:823-32. 2003
    ..These findings suggest that glioma cells resist adverse effects of hypoxia until energy stores are depleted and then undergo necrosis rather than apoptosis because of energy deprivation...
  8. ncbi request reprint Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
    Ulrich Herrlinger
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, Tubingen, Germany
    J Clin Oncol 24:4412-7. 2006
    ..To evaluate toxicity and efficacy of the combination of lomustine, temozolomide (TMZ) and involved-field radiotherapy in patients with newly diagnosed glioblastoma (GBM)...
  9. ncbi request reprint One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma
    W Wick
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen Medical School, Germany
    Neurology 62:2113-5. 2004
    ..Two patients achieved a partial response (10%), and 17 patients (81%) had stable disease. The median progression-free survival was 5 months. The progression-free survival at 6 months was 48%...
  10. ncbi request reprint Identification by suppression subtractive hybridization of p21 as a radio-inducible gene in human glioma cells
    A Rimner
    Department of Neurology, , School of Medicine, Germany
    Anticancer Res 21:3505-8. 2001
    ..We conclude that the identification of radio-inducible genomic sequences suitable for radio-gene therapy may turn out to be difficult...
  11. ncbi request reprint Radicular and nonradicular back pain in Parkinson's disease: a controlled study
    Doris Broetz
    Center for Therapy, Hertie Institute for Clinical Brain Research, School of Medicine, University of Tubingen, Tubingen, Germany
    Mov Disord 22:853-6. 2007
    ..This suggests that back pain in PD patients is often neglected and insufficiently treated. Our results argue for the routine evaluation of back pain in every patient suffering from PD...
  12. doi request reprint Hypofractionated reirradiation for recurrent malignant glioma
    Guido Henke
    Department of Radiooncology, University Hospital, Tubingen, Germany
    Strahlenther Onkol 185:113-9. 2009
    ..In order to further define the role of short-term radiotherapy as retreatment option for selected patients, we analyzed outcomes after treatment with a hypofractionated radiation...
  13. ncbi request reprint UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma
    Ulrich Herrlinger
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, Hoppe Seyler Str 3, Tubingen, D 72076, Germany
    J Neurooncol 71:295-9. 2005
    ..The median time to progression was 2.5 months. The median overall survival after start of MTX/CPM was 6.9 months (range 0.5-18.8 months). Since the progression-free survival rate at 6 months was 0%, the trial was prematurely closed...
  14. doi request reprint ACNU-based chemotherapy for recurrent glioma in the temozolomide era
    Caroline Happold
    Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tubingen, Medical School, Tubingen, Germany
    J Neurooncol 92:45-8. 2009
    ..This study does not commend ACNU as a therapy of first choice for patients with recurrent glioblastomas pretreated with temozolomide...
  15. ncbi request reprint Temozolomide: a milestone in the pharmacotherapy of brain tumors
    Michael Weller
    University of Tubingen Medical School, Department of General Neurology, Hertie Institute for Clinical Brain Research, Hoppe Seyler Strasse 3, Tubingen, Germany
    Future Oncol 1:747-54. 2005
    ..The early preliminary evidence for activity in recurrent malignant gliomas further resulted in a broad evaluation of TMZ for other tumors in neuro-oncology, mainly low-grade gliomas, brain metastases and primary cerebral lymphomas...
  16. ncbi request reprint Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Michael Weller
    Department of General Neurology, University of Tubingen, Tubingen, Germany
    Clin Cancer Res 13:6933-7. 2007
    ..Importantly, the possible effect of combined 1p/19q loss has not been studied in patients who were not treated with radiotherapy or chemotherapy...
  17. doi request reprint Ifosfamide, carboplatin and etoposide in recurrent malignant glioma
    N Schafer
    Division of Clinical Neurooncology, Department of Neurology, University of Bonn Medical Center, Sigmund Freud Strasse 25, Bonn, Germany
    Oncology 80:330-2. 2011
    ..None of the 13 patients survived progression-free for 6 months. Our retrospective analysis suggests that the ICE regimen is not effective in patients with recurrent high-grade glioma if applied at second or third relapse...
  18. doi request reprint Synthesis of cytochrome C oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death
    C Wanka
    Dr Senckenberg Institute of Neurooncology, Goethe University Frankfurt, Frankfurt, Germany
    Oncogene 31:3764-76. 2012
    ..Targeting SCO2 may therefore represent a valuable strategy to enhance sensitivity towards hypoxia and may complement strategies targeting glucose metabolism...
  19. ncbi request reprint Mechanisms of apoptosis in central nervous system tumors: application to theory
    Joachim P Steinbach
    Laboratory of Molecular Neuro Oncology, Department of Neurology, University of Tubingen, Medical School, Hoppe Seyler Strasse 3, 72076 Tubingen, Germany
    Curr Neurol Neurosci Rep 2:246-53. 2002
    ....
  20. doi request reprint Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide
    Martin Glas
    Division of Clinical Neurooncology, Department of Neurology, University of Bonn, Sigmund Freud Str 25, D 53105 Bonn, Germany
    J Clin Oncol 27:1257-61. 2009
    ..To evaluate long-term survival in a prospective series of patients newly diagnosed with glioblastoma and treated with a combination of lomustine (CCNU), temozolomide (TMZ), and radiotherapy...
  21. ncbi request reprint Apoptosis in gliomas: molecular mechanisms and therapeutic implications
    Joachim P Steinbach
    Hertie Institute for Clinical Brain Research, Department of General Neurology, School of Medicine, University of Tubingen, Tubingen, Germany
    J Neurooncol 70:245-54. 2004
    ..Yet, the induction of apoptosis plays a conceptual role in the majority of novel experimental approaches to malignant glioma which are currently evaluated in cell culture and preclinical rodent models...
  22. ncbi request reprint Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis
    Manuela Reichert
    Laboratory of Molecular Neuro Oncology, Department of Neurology, University of Tubingen, School of Medicine, Germany
    Cancer 95:1113-9. 2002
    ..Current approaches of adjuvant radiochemotherapy for patients with glioblastoma have only a modest impact on the natural course of this disease...
  23. ncbi request reprint Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma
    Jörg Wischhusen
    Laboratories of Molecular Neuro Oncology, Institute for Cell Biology, University of Tubingen, 72076 Tubingen, Germany
    Cancer Res 62:2592-9. 2002
    ..Thus, induction of B-cell and T-cell apoptosis via interactions of CD70 expressed on glioma cells and CD27 expressed on B and T cells may be a novel way for the immune escape of malignant gliomas...
  24. ncbi request reprint Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
    Antje Wick
    Department of Neurooncology, University of Heidelberg, Heidelberg, Germany
    J Clin Oncol 25:3357-61. 2007
    ..Evaluation of toxicity and efficacy of an alternating weekly regimen of temozolomide administered 1 week on and 1 week off in patients with recurrent glioma...
  25. ncbi request reprint Long-term survival with glioblastoma multiforme
    Dietmar Krex
    Department of Neurosurgery, Carl Gustav Carus University Hospital, University of Technology, Dresden, Germany
    Brain 130:2596-606. 2007
    ....